Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Current indications for axillary dissection in breast cancer

Walter Weber • 13 Mar 2025
BCC 2025
Breast Cancer

Walter Weber, MD, Basel University Hospital, Basel, Switzerland, gives an overview of the current indications for axillary dissection in patients with breast cancer. Axillary dissection is still standard in clinically node-negative patients with multiple positive sentinel nodes and in clinically node-positive patients undergoing upfront surgery, as well as in the neoadjuvant setting for patients with low-volume residual disease. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Walter Weber

PREPEC (OPBC-02): pre-pectoral vs sub-pectoral IBBR after mastectomy
0:42
PREPEC (OPBC-02): pre-pectoral vs sub-pectoral IBBR after mastectomy
Walter Weber • 30 May 2026
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
2:12
Evaluating the role of axillary surgery after neoadjuvant chemotherapy
Walter Weber • 13 Mar 2025
Selecting patients with breast cancer who can avoid axillary surgery
1:18
Selecting patients with breast cancer who can avoid axillary surgery
Walter Weber • 13 Mar 2025
St Gallen BCC 2023 highlights
0:43
St Gallen BCC 2023 highlights
Walter Weber • 17 Mar 2023

Related Videos

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
1:30
ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park • 31 May 2026
The content of VJOncology is intended for healthcare professionals